Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

181. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials

The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials 18632186 2008 11 25 2008 12 18 2016 11 22 1097-6760 52 6 2008 Dec Annals of emergency medicine Ann Emerg Med The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. 705-13 10.1016/j.annemergmed.2008.05.036 Despite guidelines recommending against opioids as first-line treatment for acute migraine, meperidine (...) is the agent used most commonly in North American emergency departments. Clinical trials performed to date have been small and have not arrived at consistent conclusions about the efficacy of meperidine. We performed a systematic review and meta-analysis to determine the relative efficacy and adverse effect profile of opioids compared with nonopioid active comparators for the treatment of acute migraine. We searched multiple sources (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

182. Migraine, vascular risk, and cardiovascular events in women: prospective cohort study.

Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. OBJECTIVES: To evaluate whether the association between migraine with aura and increased risk of cardiovascular disease is modified by vascular risk groups as measured by the Framingham risk score for coronary heart disease. DESIGN: Prospective cohort study. SETTING: Women's health study, United States. PARTICIPANTS: 27 519 women who were free from cardiovascular disease at baseline with available information (...) on the Framingham risk score and migraine status. MAIN OUTCOME MEASURES: Time to major cardiovascular disease event (non-fatal myocardial infarction, non-fatal ischaemic stroke, death from ischaemic cardiovascular disease), myocardial infarction, and ischaemic stroke. RESULTS: At baseline, 3577 (13.0%) women reported active migraine, of whom 1418 (39.6%) reported migraine with aura. During 11.9 years of follow-up, there were 697 cardiovascular disease events. We stratified participants based on 10 year risk

BMJ2008 Full Text: Link to full Text with Trip Pro

183. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine 18606965 2008 07 08 2008 07 22 2013 11 21 1526-632X 71 2 2008 Jul 08 Neurology Neurology Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. 114-21 10.1212/01.wnl.0000316800.22949.20 Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome. To investigate the efficacy and tolerability of a fixed (...) -dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine. Patients (aged 18 to 65 years) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while

EvidenceUpdates2008

184. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache.

Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. BACKGROUND: Migraine and cluster headaches are severe and disabling. Migraine affects up to 18% of women, while cluster headaches are much less common (0.2% of the population). A number of acute and prophylactic therapies are available. Hyperbaric oxygen therapy (HBOT) is the therapeutic administration of 100% oxygen at environmental pressures greater than one atmosphere, while normobaric oxygen therapy (NBOT) is oxygen (...) administered at one atmosphere. OBJECTIVES: To assess the safety and effectiveness of HBOT and NBOT for treating and preventing migraine and cluster headaches. SEARCH STRATEGY: We searched the following in May 2008: CENTRAL, MEDLINE, EMBASE, CINAHL, DORCTIHM and reference lists from relevant articles. Relevant journals were hand searched and researchers contacted. SELECTION CRITERIA: Randomised trials comparing HBOT or NBOT with one another, other active therapies, placebo (sham) interventions

Cochrane2008

185. Exercise in migraine therapy--is there any evidence for efficacy? A critical review

Exercise in migraine therapy--is there any evidence for efficacy? A critical review 18572431 2008 06 20 2008 08 26 2009 02 02 1526-4610 48 6 2008 Jun Headache Headache Exercise in migraine therapy--is there any evidence for efficacy? A critical review. 890-9 Some migraine patients find that regular exercise helps in reducing the frequency of headache attacks. In addition, exercise in migraine is recommended from many headache experts. However, most of these recommendations refer to some (...) anecdotal reports or observational studies in literature stating that regular exercise can reduce the frequency and severity of migraine. The purpose of this review is to investigate whether recommendations for exercise in migraine are based on sufficient data to cope with requirements of an evidence-based modern migraine therapy. The review summarizes and discusses all available trials on this topic. Eight studies und 4 case reports investigated the therapeutic role of aerobic exercise on migraine

EvidenceUpdates2008

186. Botulinum toxin type a as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues

Botulinum toxin type a as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues 18047501 2008 06 13 2008 08 26 2010 11 18 1526-4610 48 6 2008 Jun Headache Headache Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. 900-13 To examine the efficacy and safety of and satisfaction with botulinum toxin type A (BoNTA; BOTOX: Allergan, Inc., Irvine, CA (...) ) for prophylactic treatment of migraine headache in patients previously failing prophylaxis because of issues pertaining to compliance. Background.- Numerous factors (eg, adverse effects, tolerability, cost, frequency of dosage, hesitancy to take daily medication, failure to complete treatment) negatively influence compliance with the preventive pharmacology for migraine prophylaxis. BoNTA may offer benefit in improving compliance because of its long duration of action, injectable route of administration

EvidenceUpdates2008

187. Neuromodulators for migraine prevention

Neuromodulators for migraine prevention 18205800 2008 04 01 2008 06 17 2009 02 02 0017-8748 48 4 2008 Apr Headache Headache Neuromodulators for migraine prevention. 586-600 10.1111/j.1526-4610.2007.01040.x Migraine is a debilitating condition characterized by a cycle of painful headaches and headache-related symptoms interspersed with periods of worry, distress, and apprehension. The negative impact of migraine on patient functioning, workplace productivity, and other daily activities has been (...) demonstrated through the use of a variety of clinician- and patient-reported assessment tools, including the Migraine-Specific Questionnaire and the Migraine Disability Assessment questionnaire. In addition to considering the frequency and severity of migraine, clinicians need to encourage more open dialogue with their patients about the impact of this disorder on daily activities and productivity. Only then can the most appropriate course of treatment be determined. Appropriately prescribed acute

EvidenceUpdates2008

188. Early vs. non-early intervention in acute migraine-`Act when Mild (AwM)`. A double-blind, placebo-controlled trial of almotriptan

Early vs. non-early intervention in acute migraine-`Act when Mild (AwM)`. A double-blind, placebo-controlled trial of almotriptan 18294251 2008 03 04 2008 04 07 2012 11 15 1468-2982 28 4 2008 Apr Cephalalgia : an international journal of headache Cephalalgia Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. 383-91 10.1111/j.1468-2982.2008.01546.x The study was designed to compare the response to almotriptan (...) in migraine patients who take medication early in the course of the attack with that when medication is taken after pain has become moderate or severe. A randomized, four-arm, multicentre, multinational, double-blind, placebo-controlled trial of almotriptan (12.5 mg) comparing treatment administration when pain intensity was mild and within 1 h of headache onset vs. pain that had become moderate or severe was conducted. Of 491 migraineurs enrolled, 403 were evaluable [intention-to-treat population (ITT

EvidenceUpdates2008

189. Migraine Intervention With STARFlex Technology (MIST) trial

Migraine Intervention With STARFlex Technology (MIST) trial 18316488 2008 03 18 2008 04 03 2016 11 24 1524-4539 117 11 2008 Mar 18 Circulation Circulation Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. 1397-404 10.1161/CIRCULATIONAHA.107.727271 Patent foramen ovale (PFO (...) ) is prevalent in patients with migraine with aura. Observational studies show that PFO closure resulted in migraine cessation or improvement in approximately 80% of such patients. We investigated the effects of PFO closure for migraine in a randomized, double-blind, sham-controlled trial. Patients who suffered from migraine with aura, experienced frequent migraine attacks, had previously failed > or = 2 classes of prophylactic treatments, and had moderate or large right-to-left shunts consistent

EvidenceUpdates2008

190. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial

Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial 18302700 2008 02 27 2008 05 20 2012 11 15 0017-8748 48 3 2008 Mar Headache Headache Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. 341-54 10.1111/j.1526-4610.2007.01044.x To investigate the effect of early acute migraine intervention with almotriptan vs placebo on functional (...) disability and health-related quality of life (HRQoL) indicators. In this multicenter, double-blind, parallel-group trial, adults with international classification of headache disorders-defined migraine, with or without aura, were randomized 1:1 to treat 3 consecutive headaches with either almotriptan 12.5 mg or placebo. Patients were instructed to take their study medication at the first sign of migraine headache pain of any intensity, within 1 hour of onset. Patients recorded level of functional

EvidenceUpdates2008

191. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache

Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache 18047499 2008 02 27 2008 05 20 2013 11 21 0017-8748 48 3 2008 Mar Headache Headache Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. 333-40 Migraine headache is a common presentation in the emergency department (ED). Inflammation is thought to play a role in the pathophysiology of migraine and there is conflicting evidence regarding (...) the effect of corticosteroids on reducing early recurrences. We conducted a randomized clinical trial to test the hypothesis that dexamethasone (DEX) reduced headaches after discharge and examine the factors associated with relapse. Consenting adults (18 and older) presenting with acute migraine at 4 EDs were enrolled. In addition to standard intravenous (IV) abortive therapy, using concealed allocation patients were randomized to receive IV DEX (15 mg) or placebo (PLA) in a double-blind fashion. Relapse

EvidenceUpdates2008

192. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study

Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study 18047500 2008 02 27 2008 05 20 2012 11 15 0017-8748 48 3 2008 Mar Headache Headache Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study. 368-77 To confirm the efficacy of rizatriptan 10 mg orally disintegrating (...) tablet (ODT) for the elimination of migraine-associated nausea. Pooled studies of rizatriptan analyzing elimination of nausea as a secondary endpoint showed that 65% of rizatriptan patients reported elimination of nausea at 2 hours compared with 41% of patients taking placebo. This was a multicenter, randomized, double-blind, placebo-controlled single-attack trial enrolling adult patients with at least a 6-month history of migraine who typically experience migraine-associated nausea. Patients treated

EvidenceUpdates2008

193. Review: history and physical examination can accurately identify migraine and the need for neuroimaging in patients with headache

Review: history and physical examination can accurately identify migraine and the need for neuroimaging in patients with headache Review: history and physical examination can accurately identify migraine and the need for neuroimaging in patients with headache | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: history and physical examination can accurately identify migraine and the need for neuroimaging in patients with headache Article Text Diagnosis Review: history and physical examination can accurately identify migraine and the need

Evidence-Based Medicine (Requires free registration)2008

194. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence

Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence Colman I, Friedman B W, Brown M D, Innes G D, Grafstein E, Roberts T E, Rowe B H CRD summary (...) This review evaluated the effectiveness of parenteral corticosteroids for acute migraine headache in adults. The authors concluded that single-dose parenteral dexamethasone, when added to standard abortive treatment for migraine, is associated with a 26% relative reduction in headache recurrence within 72 hours, though not associated with initial headache pain reduction. These conclusions follow from the evidence presented in a well-conducted review. Authors' objectives To evaluate the effectiveness

DARE.2008

195. Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department: a meta-analysis and systematic review of the literature

Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department: a meta-analysis and systematic review of the literature Does the addition of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department: a meta-analysis and systematic review of the literature Does the addition (...) of dexamethasone to standard therapy for acute migraine headache decrease the incidence of recurrent headache for patients treated in the emergency department: a meta-analysis and systematic review of the literature Singh A, Alter H J, Zaia B CRD summary The authors concluded that dexamethasone was moderately effective at preventing headache recurrence when used in the emergency department as an addition to standard treatment of acute migraine headache. Side effects were mild and transient. The conclusions

DARE.2008

196. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials

The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials Friedman B W, Kapoor A, Friedman M S, Hochberg M L, Rowe B H CRD summary The authors concluded that meperidine is less effective (...) for migraine headache than dihydroergotamine regimens and may be more likely to cause adverse events. Meperidine may also be less effective than antiemetics. A degree of caution may be necessary in interpreting these conclusions because the primary trials were small, their quality was mixed and there were marked differences between them. Authors' objectives To compare the efficacy and safety of injectable opioids versus other treatments for acute migraine headache. Searching The following databases were

DARE.2008

197. Acute migraine therapy: recent evidence from randomized comparative trials

Acute migraine therapy: recent evidence from randomized comparative trials Acute migraine therapy: recent evidence from randomized comparative trials Acute migraine therapy: recent evidence from randomized comparative trials Mett A, Tfelt-Hansen P CRD summary The review found that triptan/NSAID combination therapy was more effective than one agent. All triptans were similarly effective, but almotriptan was better tolerated than sumatriptan. Limitations of the review methodology, including (...) a limited validity assessment, meant that the reliability of the results could not be assessed. Authors' objectives To assess the relative effectiveness of various medical treatments for migraine. Searching MEDLINE and EMBASE (2002 to November 2007), The Cochrane Library and Odyssey (a proprietary database of Wolters Kluwer Health) were searched for studies published in English. Search terms were listed in the review. Study selection Clinical trials of adults patients (18 to 65 years) who had at least

DARE.2008

198. Exercise in migraine therapy. Is there any evidence for efficacy: a critical review

Exercise in migraine therapy. Is there any evidence for efficacy: a critical review Exercise in migraine therapy. Is there any evidence for efficacy: a critical review Exercise in migraine therapy. Is there any evidence for efficacy: a critical review Busch V, Gaul C CRD summary The authors concluded that there was insufficient evidence to support recommendation for exercise in migraine and that further research was required. Evidence appeared to support the authors’ conclusions (...) , but the limited search and lack of reporting of review methods and assessment of study quality made it difficult to assess their reliability. Authors' objectives To examine the evidence supporting exercise for patients with migraine. Searching PubMed and Current Contents were searched from 1962 to July 2007 using reported search terms; abstract books and supplements were included in the search. In addition, "current and well-established" international textbooks were screened. Study selection Studies and case

DARE.2008

199. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine

Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine Chen L C, Ashcroft D M CRD summary The authors concluded that zolmitriptan 2.5mg tablet was effective for acute migraine with similar efficacy to almotriptan 12.5mg, eletriptan 40mg and sumatriptan 50mg and greater efficacy (...) than naratriptan 2.5mg for pain-free response at two hours. Findings that were based predominantly on single studies and incomplete reporting of review methods made it difficult to assess the reliability of the conclusions. Authors' objectives To evaluate the relative efficacy and safety of zolmitriptan for the treatment of an acute migraine attack. Searching MEDLINE, EMBASE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched from inception

DARE.2008

200. Treatment of children with migraine in the emergency department: a qualitative systematic review

Treatment of children with migraine in the emergency department: a qualitative systematic review Treatment of children with migraine in the emergency department: a qualitative systematic review Treatment of children with migraine in the emergency department: a qualitative systematic review Bailey B, McManus B C CRD summary This review aimed to assess the effectiveness of treatments administered in the emergency department for children with migraine and status migrainosus. The authors concluded (...) that there was a lack of evidence in an emergency department setting. This was a relatively well-conducted systematic review. The authors' conclusions were appropriate. Authors' objectives To assess the effectiveness of treatments administered in the emergency department for children with migraine and status migrainosus. Searching MEDLINE, EMBASE, DARE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials were searched from inception to 2007; search terms were reported

DARE.2008